drugset / Trial / NCT02472600

Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy

NCT02472600

Phase 2 Unknown 39 enrolled Stephen Harbarth European Commission · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This investigator initiated,international, multicenter open-label, randomized controlled trial aims to assess whether a 5 day course of oral nonabsorbable antibiotics (colistin sulfate 2 million IU per os 4x/day and neomycin sulfate 500 mg (salt) per os 4x/day ) followed by fecal microbiota transplantation (administered either via nasogastric administration or via capsules) is effective at eradicating intestinal carriage of beta-lactamase producing Enterobacteriaceae (ESBL-E) and carbapenemase producing Enterobacteriaceae (CPE). compared to no intervention (current standard of care) in adult non-immunosuppressed patients .

Timeline

Start
2016-02
Primary completion
2017-11-29
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Colistin Other / unclassified 2e+06 iu Oral
Comparator Neomycin Unknown 500 mg Oral
Comparator Omeprazole Other / unclassified 20 mg Oral

Indications

No indication recorded.